The EPS projection of The Medicines Company (NASDAQ:MDCO) for quarter ended 2016-09-30 is $-1.12. Last week, the projection for EPS was $-1.12 against target of $-1.12, a month earlier. While 2-months ago, this projection was $-1.12 versus forecast of $-1.12a quarter months earlier, posting a deviation of 0%.
The Medicines Company (NASDAQ:MDCO) posted that 18 days earlier, the share price was revised 0 times on upside. In addition, negative revisions were 1.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 0 and 0. While in last 120 and 90 days, positive revisions were 1, and 1, correspondingly.
The per-share earnings downgrade for The Medicines Company (NASDAQ:MDCO) in the preceding 30 and 120 were 0 and 1. While in 60 and 90 days were 0, and 1, in that order.
The Medicines Company (NASDAQ:MDCO) EPS target was $-1.12 for the quarter closed 1. It was based on 3 calls. As on 2016-05-09 the EPS was $-1.13. The change was $-0.28, posting a deviation of -32.94%. The price projections gave a standard deviation of 0.08.
Quarterly Sales Estimates
The Medicines Company (NASDAQ:MDCO) sales prediction for the fiscal 2016 stands at $38.35 and the median estimate is at $38.35. Almost 2 analysts gave sales target.
Among this, the highest sales estimate is $39.5 while the lowest target is $37.2 showing standard deviation of 1.626%.
As many as 2 analysts have positive sales targets revision while 2 reduced sales estimates, posting a deviation of 0%.
Last month, 2 experts have positive sales number revision. Also, 2 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast, posting a deviation of -26.201%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...